Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn's disease

被引：0
|
作者：
Sieczkowska, J. [1 ]
Jarzebicka, D. [1 ]
Oracz, G. [1 ]
Meglicka, M. [1 ]
Dadalski, M. [1 ]
Kierkus, J. [1 ]
机构：
[1] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol Feeding Disorders & Pa, Warsaw, Poland
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P617
引用
收藏
页码：S413 / S414
页数：2
相关论文
共 50 条
  • [41] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07): : 601 - 608
  • [42] Acute severe pulmonary toxicity due to biosimilar infliximab in a Crohn's disease patient
    Rios Leon, R.
    Jaureguizar Oriol, A.
    Lopez-Sanroman, A.
    Jimenez Castro, D.
    Nieto Royo, R.
    Albillos Martinez, A.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2019, 42 (02): : 104 - 105
  • [43] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
    Reinisch, Walter
    Gecse, Krisztina
    Halfvarson, Jonas
    Irving, Peter M.
    Jahnsen, Jorgen
    Peyrin-Biroulet, Laurent
    Rogler, Gerhard
    Schreiber, Stefan
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (01) : 106 - 122
  • [44] Myelolipoma After Infliximab Treatment for Crohn's Disease
    Cesa, Kevin
    Puppa, Elaine Leonard
    Eslami, Katayoun
    Blanchard, Samra M.
    Watkins, Runa D.
    ACG CASE REPORTS JOURNAL, 2022, 9 (07)
  • [45] Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission
    Guerrero Puente, Lourdes
    Iglesias Flores, Eva
    Manuel Benitez, Jose
    Medina Medina, Rosario
    Salgueiro Rodriguez, Isabel
    Aguilar Melero, Patricia
    Cardenas Aranzana, Manuel Jesus
    Gonzalez Fernandez, Rafael
    Manzanares Martin, Barbara
    Garcia-Sanchez, Valle
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (09): : 595 - 604
  • [46] Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients
    Eberl, Anja
    Huoponen, Saara
    Pahikkala, Tapio
    Blom, Marja
    Arkkila, Perttu
    Sipponen, Taina
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (12) : 1348 - 1353
  • [47] Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
    Milassin, Agnes
    Fabian, Anna
    Molnar, Tames
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [48] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [49] Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety
    Dipasquale, Valeria
    Romano, Claudio
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (06) : 1228 - 1234
  • [50] Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational study
    Sladek, M.
    Vultaggio, A.
    Ghione, S.
    Nencini, F.
    Matucci, A.
    Pratesi, S.
    Zanieri, F.
    Maggi, P. M.
    Paci, M.
    Ponanta-Gawron, K.
    Kulig, K.
    Wasilewska, A.
    Lionetti, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S418 - S418
12345